On May 11, 2022, Artax Biopharma, Inc. closed the transaction. The company amended the terms of the transaction and received $13,313,675 in second tranche closing. The transaction included participation from new investors Eli Lilly and Company, Sound Bioventures, returning investors Advent Life Sciences LLP, Columbus Venture Partners, S.G.E.I.C., S.A.U, Belinda Termeer and other Company shareholders.

As a part of the transaction, Casper Breum from Sound Bioventures will join the board of directors of the company. The company has received $26,000,000 in the transaction. The company received $25,785,117 pursuant to exemption provided under regulation D from 28 investors.